amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
Drug Shortage Active
ADDERALL 10 is currently in shortage. Reason: Demand increase. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
ADDERALL 10 (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate) by Teva is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 13 years, older [see clinical studies ()], older and 1 more indications. First approved in 1960.
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
ADDERALL 10 is a fixed-dose combination of amphetamine salts (aspartate, sulfate) and dextroamphetamine salts (saccharate, sulfate) administered as a 10 mg oral tablet. It is a CNS stimulant indicated for ADHD in patients 13 years and older, and has been approved since 1960. The exact mechanism of therapeutic action in ADHD is unknown, though amphetamines are thought to block reuptake and increase release of norepinephrine and dopamine.
As LOE approaches, commercial teams face declining revenue; brand defense and generic transition planning are critical near-term priorities.
non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Worked on ADDERALL 10 at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ADDERALL 10 offers limited career growth potential given its mature, LOE-approaching status and lack of clinical development pipeline. Professionals joining this team should expect focus on market defense, generic transition management, and operational efficiency rather than innovation or expansion.